Atrial Fibrillation Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

Atrial Fibrillation pipeline constitutes 5+ key companies continuously working towards developing 5+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Atrial Fibrillation Overview
Atrial Fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. During atrial fibrillation, the heart's two upper chambers (the atria) beat chaotically and irregular layout of coordination with the two lower chambers (the ventricles) of the heart.

"Atrial Fibrillation Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market.

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Atrial Fibrillation Pipeline Report https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years. Atrial Fibrillation Key players such as - Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Bioscience, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others, are developing therapies for the Atrial Fibrillation treatment
• Atrial Fibrillation Emerging therapies such as - ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.
• In February 2021, A new patent issued to ARCA by the United States Patent and Trademark Office (USPTO) for use of Gencaro in treating AF in the HF population that ARCA plans to enroll in Gencaro's planned Phase 3 development, a population that includes more than half of all HF patients in the United States and Europe. The Company believes this patent would provide effective patent coverage in the United States into 2039. ARCA has filed similar patent applications in other countries
• In January 2022, ARCA biopharma, Inc. announced that the paper entitled "Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial" (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society. The paper details an analysis that examined the prevalence of bradycardia and its association with adverse events (AEs) and failure to achieve target dose in the GENETIC-AF Phase 2b clinical trial

Atrial Fibrillation Pipeline Therapeutics Assessment
• Atrial Fibrillation Assessment by Product Type
• Atrial Fibrillation By Stage and Product Type
• Atrial Fibrillation Assessment by Route of Administration
• Atrial Fibrillation By Stage and Route of Administration
• Atrial Fibrillation Assessment by Molecule Type
• Atrial Fibrillation by Stage and Molecule Type

DelveInsight's Atrial Fibrillation Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:
• ESP-001: Espero BioPharma
• CTP-Amio: Vivasc Therapeutics
• HIP-2001: Hanmi Pharmaceutical
• VE 1902: Verseon
• HBI-3000: HUYA Bioscience
• HSY 244: Novartis
• AGN-151607: AbbVie
• Gencaro: ARCA biopharma
• Botulinum toxin A: Merz Pharma

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Assessment- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Atrial Fibrillation treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
• Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies at:
https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atrial Fibrillation Pipeline Market Drivers
• Rising prevalence of Atrial fibrillation
• Increase in the Adoption of Advanced Technologies

Atrial Fibrillation Pipeline Market Barriers
• Complications associated with the use of atrial fibrillation drugs
• Lack of awareness regarding medical therapy in underdeveloped and developing regions

Scope of Atrial Fibrillation Pipeline Drug Insight
• Coverage: Global
• Key Atrial Fibrillation Companies: Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Bioscience, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others
• Key Atrial Fibrillation Therapies: ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others
• Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
• Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Atrial Fibrillation Report Introduction
2 Atrial Fibrillation Executive Summary
3 Atrial Fibrillation Overview
4 Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment
5 Atrial Fibrillation Pipeline Therapeutics
6 Atrial Fibrillation Late Stage Products (Phase II/III)
7 Atrial Fibrillation Mid Stage Products (Phase II)
8 Atrial Fibrillation Early Stage Products (Phase I)
9 Atrial Fibrillation Preclinical Stage Products
10 Atrial Fibrillation Therapeutics Assessment
11 Atrial Fibrillation Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Atrial Fibrillation Key Companies
14 Atrial Fibrillation Key Products
15 Atrial Fibrillation Unmet Needs
16 Atrial Fibrillation Market Drivers and Barriers
17 Atrial Fibrillation Future Perspectives and Conclusion
18 Atrial Fibrillation Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Atrial Fibrillation Market https://www.delveinsight.com/report-store/atrial-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atrial Fibrillation-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Atrial Fibrillation Epidemiology https://www.delveinsight.com/report-store/atrial-fibrillation-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atrial Fibrillation Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.


Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.


Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027

To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.